99 results
8-K
EX-10.1
FGEN
FibroGen Inc
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:12pm
(the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment … or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board
8-K
EX-99.1
m13vljuozm lma2
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
pcvq 49yyhbgpv40
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
irk3i vuewcsatedyj9
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
vnswwci7 p1dm
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
8dfupf
31 May 23
Additional proxy soliciting materials
9:00am
8-K
b6d2ppjj
1 May 23
Entry into a Material Definitive Agreement
4:48pm
S-3ASR
bxnxxqu
8 Aug 22
Automatic shelf registration
5:12pm